Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI. (2013)
Attributed to:
Evaluation of non-invasive metabolic imaging biomarkers for novel RAF/MEK1/2-targeted anti-cancer agents
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1038/bjc.2013.456
PubMed Identifier: 23942066
Publication URI: http://europepmc.org/abstract/MED/23942066
Type: Journal Article/Review
Volume: 109
Parent Publication: British journal of cancer
Issue: 6
ISSN: 0007-0920